SHANGHAI, July 11,
2024 /PRNewswire/ -- Recently, BioGeometry and
Sanyou Bio jointly announced the signing of a strategic partnership
agreement.
BioGeometry is a digital biology pioneer company that
specializes in AI-driven protein design and R&D platform.
Sanyou Bio is a world-leading high-tech biotechnology enterprise
focusing on R&D and services of innovative biologic drugs.
Both parties will leverage their respective expertise in
generative AI technology and practical experience of drug
development from target discovery to Investigational New Drug (IND)
application, to create a next-generation antibody drug discovery
platform driven by AIGC and jointly promote trilateral cooperation
with leading innovative pharmaceutical companies or biotechs to
enhance the efficiency of new drug R&D and help pharmaceutical
R&D enterprises improve global competitiveness.
In this strategic cooperation, Sanyou Bio will integrate
BioGeometry's proprietary generative AI antibody design platform
(GeoBiologics). Both parties will invest their respective
advantageous resources, professional technologies and experiences
to create an outstanding Dry-Wet antibody R&D platform by
integrating BioGeometry's leading AI algorithm dry lab
platform with Sanyou Bio's wet lab capabilities. This platform will
be utilized for the development of more large molecule drug
pipelines and the incubation of innovative projects, paving the way
for further market expansion.
Sanyou has built a world-leading high-throughput, and integrated
R&D platform for innovative antibody drugs, accumulating and
forming the world's largest antibody library and other technical
resources. The antibody library construction platform, based on
nine super-trillion antibody libraries as its core, has a capacity
of up to 10 trillion. It seamlessly integrates phage display and
mammalian cell protein expression of molecule generation
technologies. Equipped with fully automated screening and
integrated antibody drug R&D capabilities, it is suitable for
challenging innovative targets and the development of
high-difficulty new molecules, with a focus on generating molecules
with characteristics such as "close to natural, high affinity, and
excellent developability". The
platform has strong wet experimental capabilities and data
advantages.
As a leading AI-driven protein design enterprise, BioGeometry
has developed atomic-level geometric deep learning models which
learn from massive data to effectively save the time and costs in
antibody design, improve economic efficiency and success rates.
Moreover, BioGeometry has achieved a closed-loop between dry and
wet lab on its generative AI antibody discovery SaaS platform,
GeoBiologics. Molecules generated or optimized by AI models are
further validated and screened through high-throughput wet-lab
experiments. At the same time, the experimental data is fed back to
the AI models to enhance prediction accuracy and confidence.
Through multiple rounds of AI design and wet-lab validation,
functional molecules can be discovered more efficiently.
Dr. Guojun Lang, founder and CEO
of Sanyou Bio, remarked: "BioGeometry's generative AI technology
has enabled Sanyou to achieve intelligent and digital
transformation of our antibody drug R&D platform, further
strengthening our advantages in new drug discovery and preclinical
integration. We believe that the AIGC antibody drug discovery
platform created through our collaboration with BioGeometry will
provide more innovative solutions for new drug R&D enterprises,
accelerate the preclinical research of more new drugs, and even
facilitate their entry into clinical trials, thereby enhancing
global competitiveness of pharmaceutical R&D enterprises."
Dr. Jian Tang, founder and CEO of
BioGeometry, stated: "We look forward to jointly creating with
Sanyou Bio a cutting-edge AI-enabled antibody discovery platform
combining dry and wet labs. This platform aims to become an
innovative model for AI-empowered new drug R&D leading the
industry, and accelerate the development of antibody drug R&D
and fully enter the era of artificial intelligence. We hope to
incubate and advancing more large-molecule drug pipelines through
our platform, jointly overcoming more challenges in antibody drug
R&D, and making substantive contributions to the progress of
global disease treatment."
About BioGeometry
BioGeometry is a generative AI-driven protein design and R&D
platform company committed to providing biomanufacturing solutions
to traditional manufacturing industries, achieving green and
intelligent transformation. The company constructs generative
artificial intelligence (AIGC) large-models to understand the
language of life, building multimodal large-models that bridge
natural language and protein language to reinvent the process of
protein drug discovery and design. Dedicated to creating
programmable proteins, BioGeometry applies these innovations in
biopharmaceuticals and biomaterial production. By applying their
expertise to drug development, BioGeometry addresses traditional
challenges in large-molecule drug manufacturing, such as high
costs, lengthy processes, low success rates, and difficulties in
formulation, thus offering innovative drugs to save patients'
lives.
Founded in 2022 by Dr. Jian Tang,
a renowned scientist in AI4Drug and deep learning on graphs, with
Turing Award laureate Yoshua Bengio
serving as the chief scientific advisor, the company has built two
foundational platforms: an AI-driven large molecule drug design
platform and high-throughput wet-lab validation, creating a
closed-loop system that empowers partners to achieve precise and
efficient large molecule drug design and optimization.
Business Cooperation: bd@biogeom.com
Official Website: www.biogeom.com
About Sanyou Bio
Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech
biotechnology enterprise focusing on R&D and services of
innovative biologic drugs. Sanyou has built the 4C business
patterns that integrate "differentiated CRO, integrated CDO,
innovative CPO and characteristic CRS", to accomplish the mission
"to make the R&D easy for innovative biologics".
Sanyou has established an integrated innovative biologic drug
R&D laboratory with advanced facilities, and has a professional
team with the majority holding a Ph.D. or master degree. Sanyou has
built three industry-leading innovative technology platforms
featured by "super-trillion, integration, and intelligence", which
are comprised of more than 50 sub-platforms with the core
innovative super-trillion phage display platform, and supported by
platforms of material preparation, biologics discovery, molecule
optimization, in vitro and in vivo efficacy, production cell
line construction, upstream and downstream process development,
preclinical R&D, industrialization development, etc.
Sanyou's business network has expanded to all parts of the
world, including Asia, US and
Europe, and established branches
in Boston, Philadelphia, San
Diego and London. Sanyou
has established friendly business relationships with more than 1000
pharmaceutical companies, drug R&D institutions and diagnostics
companies worldwide. Sanyou received National-level certification
as a high-tech enterprise and a Specialized and Sophisticated
enterprise, and passed the ISO9001 quality assurance certification
and GB/T intellectual property management system certification.
Business Cooperation: service@sanyoubio.com
Official Website: www.sanyoubio.com
View original
content:https://www.prnewswire.com/news-releases/sanyou-bio-and-biogeometry-join-forces-to-create-a-next-generation-antibody-drug-discovery-platform-driven-by-aigc-302194592.html
SOURCE Sanyou Bio